Transcat Inc. filings document material events for a calibration services and test-instrument distribution company. Recent Form 8-K reports cover quarterly results furnished under Item 2.02, earnings press releases and presentation exhibits, and Regulation FD disclosures tied to operating updates.
The company’s filings also record governance and equity-compensation matters, including executive appointments, officer transitions, retention equity awards, and transition agreements. Acquisition-related 8-K disclosures describe completed purchases of calibration laboratory businesses, related material agreements, consideration, exhibits, and customary representations, warranties and holdback provisions.
TRANSCAT INC (TRNS) director Robert Mecca reported equity compensation activity. On September 9, 2026, he received 1,671 Restricted Stock Units (RSUs) that, except as otherwise provided in the award agreement, vest on September 9, 2027, and convert into common stock on a one-for-one basis. On September 10, 2026, 1,587 RSUs vested and were converted into 1,587 shares of common stock, leaving him with 2,291 common shares held directly. He also reports a stock option on 10,000 underlying shares at an exercise price of $98.88 per share, vesting pro rata over five years and expiring January 24, 2034. No transactions were made under a Rule 10b5-1 trading plan.
TRANSCAT INC (TRNS) director Cynthia Langston reported equity compensation activity involving restricted stock units (RSUs), common stock, and stock options. On September 10, 2026, RSUs covering 1,587 shares converted one-for-one into common stock at no cash exercise price, increasing her directly held common shares to 3,424. On September 9, 2026, she received a grant of 1,671 RSUs that, except as otherwise provided in the award agreement, vest on September 9, 2027. She also holds a stock option for 10,000 underlying shares at an exercise price of $73.80 per share, vesting pro rata over five years and expiring on September 7, 2032. No transactions were reported under a Rule 10b5-1 trading plan.
TRANSCAT INC (TRNS) director Kaniki Mbago M. reported equity award and vesting activity. On September 9, 2026, the director received 1,671 restricted stock units (RSUs), which vest on September 9, 2027. On September 10, 2026, 1,587 RSUs vested and converted 1-for-1 into common shares, increasing direct common stock holdings to 4,180 shares. The director also holds a fully vested stock option covering 10,000 shares at an exercise price of $47.14 per share, expiring May 12, 2031. No Rule 10b5-1 trading plan is reported.
TRANSCAT INC (TRNS) director Gary J. Haseley reported equity compensation activity involving restricted stock units (RSUs) and common stock. On September 9, 2026 he received a grant of 1,671 RSUs that, except as otherwise provided, vest on September 9, 2027 and convert into common stock on a one-for-one basis. On September 10, 2026, 1,587 previously granted RSUs vested and were converted into 1,587 shares of common stock at no cash exercise price, increasing his direct common stock holdings to 40,689 shares. He also reports 1,200 shares of common stock held indirectly by family trusts. No Rule 10b5-1 trading plan is reported for these transactions.
TRANSCAT INC (TRNS) director Christopher P. Gillette reported equity-compensation activity involving restricted stock units (RSUs), common stock, and stock options. On September 10, 2026, 1,587 RSUs vested and converted one-for-one into 1,587 shares of common stock, bringing his directly held common stock to 1,787 shares. On September 9, 2026, he received a grant of 1,671 RSUs, granted in a transaction exempt under Rule 16b-3, which are scheduled to vest on September 9, 2027, subject to the award agreement. He also holds a stock option covering 10,000 underlying common shares at an exercise price of $109.55 per share, expiring on September 6, 2033, vesting pro rata in five annual installments. No market purchases or sales of common stock are reported, and no Rule 10b5-1 trading plan is indicated.
TRANSCAT INC (TRNS) director Oksana S. Dominach reported equity award activity involving Restricted Stock Units (RSUs) tied to common stock. On September 9, 2026, she received a grant of 1,671 RSUs that vest on September 9, 2027 in a transaction exempt under Rule 16b-3. On September 10, 2026, 1,587 RSUs vested and converted one-for-one into 1,587 common shares, increasing her direct common stock holdings to 5,933 shares. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
TRANSCAT INC (TRNS) director Dawn DePerrior reported equity compensation activity involving restricted stock units (RSUs), common stock, and stock options. On September 9, 2026, she received 1,671 RSUs that convert one-for-one into common stock and, except as otherwise provided, vest on September 9, 2027. On September 10, 2026, 1,587 RSUs vested and were converted into 1,587 shares of common stock, bringing her directly held common stock to 2,291 shares. She also holds a stock option for 10,000 underlying shares at an exercise price of $92.92 per share, which vests pro rata in five equal annual installments and expires on October 26, 2033. No Rule 10b5-1 trading plan is reported.
TRANSCAT INC (TRNS) director Craig D. Cairns reported equity award activity and related share issuances. On September 9, 2026, he received 1,671 Restricted Stock Units that convert into common stock on a one-for-one basis and, except as otherwise provided in the award agreement, vest on September 9, 2027. On September 10, 2026, 1,587 RSUs vested and were converted into 1,587 shares of common stock, increasing his direct common stock holdings to 6,590 shares. He also reports a fully vested stock option covering 10,000 shares at an exercise price of $47.14 per share, expiring May 12, 2031, plus indirect holdings through 401(k) plans.
Transcat, Inc. (TRNS) reported the results of its September 9, 2026 annual shareholder meeting. Shareholders elected six directors—Dawn G. DePerrior, Christopher P. Gillette, Gary J. Haseley, Mbago M. Kaniki, Cynthia M. Langston, and Robert L. Mecca—to one-year terms expiring in 2027.
Shareholders also approved on an advisory basis the compensation of the company’s named executive officers, with 7,921,274 votes for, 153,061 against, 4,421 abstentions, and 614,849 broker non-votes. In addition, shareholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending March 27, 2027, with 8,692,380 votes for, 868 against, and 357 abstentions.
Transcat, Inc. (TRNS) has filed a Form S-3 to register for resale up to 17,204 shares of its common stock owned by certain selling shareholders. These shares are remaining holdback shares issued as part of Transcat’s August 2023 acquisition of Axiom Test Equipment, Inc., a U.S. rental provider of electronic test equipment.
The offering is purely a secondary resale: Transcat is not selling any shares and will receive no proceeds from sales under this prospectus, though it will bear an estimated $110,000 of registration-related expenses. As of August 31, 2026, there were 9,388,294 Transcat shares outstanding, and the stock last traded at $86.49 per share on the Nasdaq Global Market.
Transcat describes itself as a leading provider of accredited calibration and related services and a value-added distributor serving highly regulated industries, particularly life sciences, aerospace and defense, and energy and utilities. The filing also notes that Deloitte & Touche LLP issued an adverse opinion on the effectiveness of internal control over financial reporting, even as it gave an unqualified opinion on the financial statements, signaling that internal control remediation remains a key focus area.